// App-Quantinova.ai

2583 : AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

Researchers

Presenter

  • Sophia Frentzas

Principal Investigators

  • Tarek Meniawy

  • Steven Chuan-Hao Kao

  • Ruihua Wang

  • Yunxia Zuo

  • Hao Zheng

  • Wei Tan

Medical Centers

  • Medical Oncology, Monash Health, Clayton, Victoria, Australia

  • School of Medical and Health Sciences, Monash University, Melbourne, VIC, Australia

  • Edith Cowan Univ, Joondalup, WA, Australia

  • Australia

  • School of Medicine, University of Western Australia

  • Crawley, Western Australia

  • Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, Australia

  • Chris O’Brien Life House, School of Medicine, University of Sydney, Sydney, NSW, Australia

  • BeiGene Co., Ltd., Shanghai, China

  • BeiGene USA, Inc., San Mateo, CA

Locations

  • Australia

  • United States

  • United Kingdom

  • China

Companies

  • BeiGene USA, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Tislelizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT04047862

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved